Skip to main content
. Author manuscript; available in PMC: 2014 Dec 15.
Published in final edited form as: Leuk Lymphoma. 2012 Sep 5;54(3):619–630. doi: 10.3109/10428194.2012.720979

Figure 4.

Figure 4

Bcr–abl activates the PTPN13 promoter in a tyrosine kinase dependent manner. (A) Bcr–abl induces activation of the PTPN13 promoter in a tyrosine kinase dependent manner. U937 cells were co-transfected with a reporter vector with 670 bp of the PTPN13 promoter (or empty control vector), and a vector to express Bcr–abl (or empty expression vector). Transfectants were analyzed for luciferase reporter expression with versus without various amounts of the tyrosine kinase inhibitor, imatinib (IM). Statistically significant differences in reporter expression are indicated by *, ** or *** (p<0.001, n = 4). (B) Bcr–abl increases Fap1 mRNA expression in U937 transfectants. U937 cells were transfected with a vector to express Bcr–abl (or empty vector control). Cells were analyzed with or without treatment with IM (2.0 μM) for expression of Icsbp and Fap1 by real time PCR. Statistically significant differences are indicated by *, **, ***, #, ## or ### (p< 0.001, n = 3).